```
=> FIL HCAPLUS
FILE 'HCAPLUS' ENTERED AT 17:23:55 ON 18 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 18 Mar 2003  VOL 138 ISS 12
FILE LAST UPDATED: 17 Mar 2003  (20030317/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=>
=>
=> D STAT QUE L13
L5             3 SEA FILE=REGISTRY ABB=ON  PLU=ON  C21H32N8O7S/MF
L12           15 SEA FILE=REGISTRY ABB=ON  PLU=ON  (403669-36-3/RN OR 403669-23-
                 8/RN) OR 243969-94-0/RN OR C18H33CLN6O6/MF OR 403669-27-2/RN
                 OR 403669-12-5/RN OR 403669-28-3/RN OR 403669-30-7/RN OR
                 403669-33-0/RN OR (180470-75-1/RN OR 180312-24-7/RN) OR
                 180313-26-2/RN OR L5 OR 403669-35-2/RN OR 403669-38-5/RN OR
                 403669-41-0/RN
L13            5 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L12


=>
=>

=> D IBIB ABS HITRN L13 1-5

L13  ANSWER 1 OF 5  HCAPLUS  COPYRIGHT 2003 ACS
ACCESSION NUMBER:         2003:203392  HCAPLUS
TITLE:                    Preparation of peptides as inhibitors of serine
                          protease activity of matriptase or MTSP1
INVENTOR(S):              Semple, Joseph E.; Coombs, Gary S.; Reiner, John E.;
                          Ong, Edgar O.; Araldi, Gian Luca
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of Appl.
                          No. PCT/US01/28137.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   4
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ----------------  ----  --------      ---------------  --------
     US 2003050251      A1   20030313      US 2002-92004    20020305
     WO 2002020475      A2   20020314      WO 2001-US28137  20010907
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
```

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-657986 A2 20000908
WO 2001-US28137 A2 20010907

my appl.

GI



I

AB The invention provides compds. I [X = CO, CO2, CONH, SO2, SO2NH or a direct link; R1 = (un)substituted alkyl, cycloalkyl, aryl, heterocycloalkyl, H when X is CONH, SO2, SO2NH or a direct link, etc.; R2 = H, alkyl; n = 0-3; R3 = H, Me; R4a, R4b = H, alkyl; q = 0-2; when q = 0, R3 and R4a form prolyl or prolyl derivs., pipecolyl, or azetidine-2-carbonyl groups which are in the S-configuration; E is a 5- or 6-membered arom. ring having 0-2 ring heteroatoms; T is H, OH, CH2OH, alkyl, cyano, an amidino, guanidino, amino or carbamoyl deriv.] which inhibit serine protease activity of matriptase or MTSP1. Also provided are pharmaceutical compns. for treating conditions ameliorated by inhibition of matriptase or MTSP1. Thus, (R)-5-[3-(diaminomethyl)phenyl]-4-[(1-formyl-(S)-4-guanidinobutylcarbamoylmethyl)carbamoyl]-4-(methoxycarbonylamino)pentanoic acid tert-Bu ester was prepd. and showed IC50 < 100 nM for inhibition of matriptase activity.

IT **180312-24-7P 243969-94-0P 403669-12-5P**
403669-23-8P 403669-24-9P 403669-27-2P
403669-28-3P 403669-30-7P 403669-33-0P
403669-35-2P 403669-36-3P 403669-38-5P
403669-41-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptides as inhibitors of serine protease activity of matriptase or MTSP1)

L13 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:185072 HCAPLUS
DOCUMENT NUMBER: 136:232549
TITLE: Preparation of peptides as inhibitors of serine protease activity of matriptase or MTSP1
INVENTOR(S): Duncan, David F.; Madison, Edwin L.; Semple, Joseph Edward; Coombs, Gary Samuel; Reiner, John Eugene; Ong, Edgar O.; Araldi, Gian Luca
PATENT ASSIGNEE(S): Corvas International, Inc., USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020475	A2	20020314	WO 2001-US28137	20010907
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001088922	A5	20020322	AU 2001-88922	20010907
US 2003050251	A1	20030313	US 2002-92004	20020305

PRIORITY APPLN. INFO.: US 2000-657986 A 20000908
WO 2001-US28137 W 20010907

OTHER SOURCE(S): MARPAT 136:232549

GI



I

AB The invention provides compds. I [X = CO, CO2, CONH, SO2, SO2NH or a direct link; R1 = (un)substituted alkyl, cycloalkyl, aryl, heterocycloalkyl, H when X is CONH, SO2, SO2NH or a direct link, etc.; R2 = H, alkyl; n = 0-3; R3 = H, Me; R4a, R4b = H, alkyl; q = 0-2; when q = 0, R3 and R4a form prolyl or prolyl derivs., pipecolyl, or azetidine-2-carbonyl groups which are in the S-configuration; E is a 5- or 6-membered arom. ring having 0-2 ring heteroatoms; T is H, OH, CH2OH, alkyl, cyano, an amidino, guanidino, amino or carbamoyl deriv.] which inhibit serine protease activity of matriptase or MTSP1. Also provided are pharmaceutical compns. for treating conditions ameliorated by inhibition of matriptase or MTSP1. Thus, (R)-5-[3-(diaminomethyl)phenyl]-4-[(1-formyl-(S)-4-guanidinobutylcarbamoylmethyl)carbamoyl]-4-(methoxycarbonylamino)pentanoic acid tert-Bu ester was prepd. and showed IC50 < 100 nM for inhibition of matriptase activity.

IT **180312-24-7P 243969-94-0P 403669-12-5P**
403669-23-8P 403669-24-9P 403669-27-2P
403669-28-3P 403669-30-7P 403669-33-0P
403669-35-2P 403669-36-3P 403669-38-5P
403669-41-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptides as inhibitors of serine protease activity of matriptase or MTSP1)

L13 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:113118 HCAPLUS
DOCUMENT NUMBER: 132:152140
TITLE: Preparation of N-substituted glycine derivatives as enzyme inhibitors
INVENTOR(S): Abelman, Matthew Mark; Miller, Todd Anthony; Nutt,

Ruth Foelsche
PATENT ASSIGNEE(S): Corvas International, Inc., USA
SOURCE: U.S., 67 pp., Cont.-in-part of U.S. 5,696,231.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6025472	A	20000215	US 1995-484509	19950607
US 5696231	A	19971209	US 1994-361794	19941221
CA 2207373	AA	19960627	CA 1995-2207373	19951221
WO 9619493	A1	19960627	WO 1995-US16866	19951221
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9646086	A1	19960710	AU 1996-46086	19951221
AU 716995	B2	20000316		
EP 801654	A1	19971022	EP 1995-944234	19951221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
BR 9510264	A	19971104	BR 1995-10264	19951221
CN 1171116	A	19980121	CN 1995-196925	19951221
HU 77524	A2	19980528	HU 1998-71	19951221
JP 10512550	T2	19981202	JP 1995-520031	19951221
NZ 300829	A	20010330	NZ 1995-300829	19951221

PRIORITY APPLN. INFO.: US 1994-361794 A2 19941221
US 1995-484509 A 19950607
WO 1995-US16866 W 19951221

OTHER SOURCE(S): MARPAT 132:152140
GI



I

AB Glycine derivs. I [X = SO2, NR'SO2, CO, O2C, NHCO, P(O)R'', bond; R' = H, alkyl, aryl, aralkyl; R'' = NR', OR', R', SR'; R1 = H, substituted benzyl or naphthyl; R2 = H, tetrazol-5-ylalkyl, tetrazol-5-ylalkylsulfonylmethyl, pyridin-3-ylalkyl, H, 3-guanidinopropyl, 2-methylsulfonylethyl, etc.; R3 = H, cycloalkyl, (un)substituted alkyl or aryl; R4 = H, (un)substituted alkyl or aryl] were prepd. as potent inhibitors of factor Xa. Thus, D-camphorsulfonyl-D-arginine-sarcosine-arginine aldehyde, prepd. by soln. phase methods, inhibited factor Xa catalytic activity with IC50 = 8.2 nM.

IT **180312-24-7P 180470-75-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-substituted glycine derivs. as enzyme inhibitors)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:606981 HCAPLUS
DOCUMENT NUMBER: 131:229021
TITLE: Preparation of peptide aldehyde analogs as inhibitors of thrombosis
INVENTOR(S): Vlasuk, George Phillip; Webb, Thomas Roy; Abelman, Matthew Mark; Pearson, Daniel Andrew; Miller, Todd Anthony
PATENT ASSIGNEE(S): Corvas International, Inc., USA
SOURCE: U.S., 82 pp., Cont.-in-part of U. S. 5,492,895.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5955576	A	19990921	US 1995-484269	19950607
US 5492895	A	19960220	US 1994-195995	19940211

PRIORITY APPLN. INFO.: US 1992-836123 B2 19920214
US 1993-17125 B2 19930212
US 1994-195995 A2 19940211

OTHER SOURCE(S): MARPAT 131:229021
GI



I

AB Peptide aldehyde analogs I [R1 = alkyl, cycloalkylalkyl, alkenyl, (un)substituted aryl, aralkyl, or aralkenyl, perfluoroalkyl, camphoryl, etc.; X = SO2, NHSO2, CO, OCO, NHCO, etc.; m = 1-5; R2 = H, 3-pyridylmethyl, substituted 5-tetrazolylalkyl, CO2H, etc.; R3 = (CH2)3NHC(:NH)NH2] or their pharmaceutically acceptable salts. were prepd. as thrombin inhibitors. Thus, N-(3-phenylpropionyl)-L-aspartyl-L-prolyl-L-argininal was prepd. by the solid-phase method and showed IC50 values 92, 52, 481 nM, resp., for inhibition of thrombin, Factor Xa, and plasmin in vitro, vs. 3.6, 5,300, and 144 nm for the control aldehyde Boc-D-Phe-Pro-Arg-H.

IT **243969-94-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of peptide aldehyde analogs as antithrombotics)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:527345 HCAPLUS
DOCUMENT NUMBER: 125:196382
TITLE: Preparation of peptide aldehydes as inhibitors of factor Xa.
INVENTOR(S): Abelman, Matthew Mark; Miller, Todd Anthony; Nutt, Ruth Foelsche
PATENT ASSIGNEE(S): Corvas International, Inc., USA
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9619493	A1	19960627	WO 1995-US16866	19951221
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5696231	A	19971209	US 1994-361794	19941221
US 6025472	A	20000215	US 1995-484509	19950607
AU 9646086	A1	19960710	AU 1996-46086	19951221
AU 716995	B2	20000316		
EP 801654	A1	19971022	EP 1995-944234	19951221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
BR 9510264	A	19971104	BR 1995-10264	19951221
JP 10512550	T2	19981202	JP 1995-520031	19951221
NZ 300829	A	20010330	NZ 1995-300829	19951221

PRIORITY APPLN. INFO.:
US 1994-361794 A 19941221
US 1995-484509 A 19950607
WO 1995-US16866 W 19951221

OTHER SOURCE(S): MARPAT 125:196382
GI



I



II

AB Title compds. [I; X = SO2, NR'SO2, CO, O2C, NHCO, P(O)R'', bond; R' = H, alkyl, aryl, aralkyl; R'' = NR', OR', R', SR'; R1 = H, (substituted) alkyl, cycloalkyl, heterocycloalkyl, heterocyclyl, alkenyl, aryl, heteroaryl, aralkyl, aralkenyl, CHF2, perfluoroalkyl, perfluoroaryl, etc.; R2 = H, tetrazol-5-ylalkyl, tetrazol-5-ylalkylsulfonylmethyl, pyridin-3-ylalkyl, guanidinoalkyl, methylsulfonylalkyl, etc.; R3 = H, (substituted) alkyl, cycloalkyl, aryl; R4 = H, (substituted) alkyl; with provisos], were prepd. Thus, title compd. (II), prepd. by soln. phase methods, inhibited factor Xa catalytic activity with IC50 = 1.7 nM.

IT **180312-24-7P 180313-26-2P 180470-75-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptide aldehydes as inhibitors of factor Xa)

=>
=>

=> FIL CAOLD
FILE 'CAOLD' ENTERED AT 17:24:27 ON 18 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for

more information.

=>
=>

=> S L12
L14 0 L12

=>
=>

=> FIL REG
FILE 'REGISTRY' ENTERED AT 17:24:39 ON 18 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 MAR 2003 HIGHEST RN 499763-93-8
DICTIONARY FILE UPDATES: 17 MAR 2003 HIGHEST RN 499763-93-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
=>

=> D IDE CAN L12 TOT

L12 ANSWER 1 OF 15 REGISTRY COPYRIGHT 2003 ACS
RN **403669-41-0** REGISTRY
CN Glycinamide, 3-[1-(aminoiminomethyl)-4-piperidinyl]-N-[(phenylmethyl)sulfonyl]-D-alanyl-N-[[5-(aminoiminomethyl)-2-thienyl]methyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C24 H34 N8 O4 S2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



#23

23 exactly

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:232549

L12 ANSWER 2 OF 15 REGISTRY COPYRIGHT 2003 ACS
RN **403669-38-5** REGISTRY
CN Glycinamide, N-[[[3-[imino(methylamino)methyl]phenyl]methyl]sulfonyl]-L-.alpha.-glutamyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H34 N8 O7 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.

#20



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:232549

L12 ANSWER 3 OF 15 REGISTRY COPYRIGHT 2003 ACS
RN **403669-36-3** REGISTRY
CN Glycinamide, N-[[[3-(aminoiminomethyl)phenyl]methyl]sulfonyl]-L-.alpha.-glutamyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C21 H32 N8 O7 S**
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



#18

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:232549

L12 ANSWER 4 OF 15 REGISTRY COPYRIGHT 2003 ACS
RN **403669-35-2** REGISTRY
CN L-Alaninamide, N-[(phenylmethoxy)carbonyl]-D-homoseryl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H32 N6 O6
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



#14

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:232549

L12 ANSWER 5 OF 15 REGISTRY COPYRIGHT 2003 ACS
RN **403669-33-0** REGISTRY
CN Glycinamide, N-[[2-(aminoiminomethyl)phenyl]sulfonyl]-L-.alpha.-glutamyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]-N2-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C21 H32 N8 O7 S**
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:232549

L12 ANSWER 6 OF 15 REGISTRY COPYRIGHT 2003 ACS
RN **403669-30-7** REGISTRY
CN 1H-1-Benzazepine-1-acetamide, N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]-2,3,4,5-tetrahydro-7-methoxy-2-oxo-3-[[(phenylmethyl)sulfonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H34 N6 O6 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



#9 already exists.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:232549

L12 ANSWER 7 OF 15 REGISTRY COPYRIGHT 2003 ACS
RN **403669-28-3** REGISTRY
CN Glycinamide, N-[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]sulfonyl]-L-.alpha.-glutamyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H32 N8 O8 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



#7

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:232549

L12 ANSWER 8 OF 15 REGISTRY COPYRIGHT 2003 ACS
RN **403669-27-2** REGISTRY
CN Glycinamide, 2-[[3-(aminoiminomethyl)phenyl]methyl]-N-[(phenylmethyl)sulfonyl]-D-.alpha.-glutamyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H38 N8 O7 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



#6

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:232549

L12 ANSWER 9 OF 15 REGISTRY COPYRIGHT 2003 ACS
RN 403669-24-9 REGISTRY
CN L-Alaninamide, N-[(2-methylpropoxy)carbonyl]-L-seryl-N-[4-[(aminoiminomethyl)amino]-1-(chloroacetyl)butyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C18 H33 Cl N6 O6**
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



#3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:232549

L12 ANSWER 10 OF 15 REGISTRY COPYRIGHT 2003 ACS
RN **403669-23-8** REGISTRY
CN Glycinamide, N-[[[4-(aminoiminomethyl)phenyl]methyl]sulfonyl]-L-.alpha.-glutamyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C21 H32 N8 O7 S**
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



#1

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:232549

L12 ANSWER 11 OF 15 REGISTRY COPYRIGHT 2003 ACS
RN **403669-12-5** REGISTRY
CN Glycinamide, 2-[[3-(aminoiminomethyl)phenyl]methyl]-N-[(phenylmethyl)sulfonyl]-L-.alpha.-glutamyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H38 N8 O7 S

SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



#6

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:232549

L12 ANSWER 12 OF 15 REGISTRY COPYRIGHT 2003 ACS
RN **243969-94-0** REGISTRY
CN L-Prolinamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-N2-(1-oxo-2-propylpentyl)-L-asparaginyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H52 N8 O5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



#2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:232549

REFERENCE 2: 131:229021

L12 ANSWER 13 OF 15 REGISTRY COPYRIGHT 2003 ACS

RN **180470-75-1** REGISTRY
CN Butanamide, N-[2-[[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]amino]-2-oxoethyl]-2-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-N-methyl-4-(methylsulfonyl)-, (2R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glycinamide, N-[[(7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methyl]sulfonyl]-4-(methylsulfonyl)-D-2-aminobutanoyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-N2-methyl-, [1(1S),2(S)]-
FS STEREOSEARCH
MF C24 H42 N6 O8 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



#16

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 132:152140

REFERENCE 2: 125:196382

L12 ANSWER 14 OF 15 REGISTRY COPYRIGHT 2003 ACS
RN **180313-26-2** REGISTRY
CN Glycinamide, N2-[(4-methylphenyl)sulfonyl]-D-arginyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-N2-methyl-, (S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H37 N9 O5 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 125:196382

L12 ANSWER 15 OF 15 REGISTRY COPYRIGHT 2003 ACS
RN **180312-24-7** REGISTRY
CN Butanamide, N-[2-[[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]amino]-2-oxoethyl]-2-[[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]amino]-N-methyl-4-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glycinamide, N-[[(7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methyl]sulfonyl]-4-(methylsulfonyl)-L-2-aminobutanoyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-N2-methyl-, [1(1S),2(S)]-
FS STEREOSEARCH
MF C24 H42 N6 O8 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
4 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:232549

REFERENCE 2: 132:152140

REFERENCE 3: 125:196382